Strategic licensing Eton has secured an exclusive US license and supply agreement for Libervant diazepam buccal film from Aquestive Therapeutics, indicating a strong near-term expansion into epilepsy seizure cluster treatments and a built-in partner for commercialization and milestones.

Launch readiness With a planned US launch of Libervant in April 2027 pending FDA approval, there is a clear opportunity to engage regulatory, payer, and specialty distribution channels early to ensure market access and rapid uptake post-approval.

Rare-disease portfolio Recent relaunch and expansion of Impavido for exclusive US commercialization signals a growing rare-disease franchise, presenting cross-sell opportunities with specialty distributors and patient support programs.

Financial momentum Solid revenue trajectory and a notable earnings beat bolster credibility for partnerships, while ongoing milestones from licensing arrangements offer predictable revenue milestones and collaboration potential.

Strategic partnerships Active participation in major investor conferences and collaboration with a pharma licensee partner creates openings for co-marketing, joint distribution arrangements, and expanded access programs targeting seizures, rare diseases, and orphan indications.